novo nordisk glp-1 medications Details of failed studies cast pall on Nordisk's as Alzheimer's treatment Novo Nordisk justifies reasoning behind
Description
[DOI] [PubMed] [Google Scholar] 31.St-Pierre J., Klein J., Choi N.K., Fear E., Pannain S., Rubin D.T
Some patients may experience headache as their body adapts to improved glycaemic control, especially if they were previously accustomed to higher blood glucose levels
At multivariate Cox regression analysis, diabetes duration (HR 1.08, 95% CI 1.021.14, P = 0.008) was the independent risk factor, and GLP-1 RAs therapy (HR 0.42, 95% CI: 0.200.88, P = 0.022) was the independent protective factor for the occurrence of MACEs in this population
Repost to share the impacts of these major GLP-1 price cuts
